1. What is Mazdutide?
Mazdutide (also known as IBI-362 / LY3305677) is an investigational, long-acting peptide that co-activates the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). It is being evaluated in clinical research for effects on body-weight regulation, glycemic control, and broader metabolic health. Recent peer-reviewed reports describe clinically meaningful weight reduction in adults with overweight or obesity.
2. Mazdutide Structure
Molecular Formula：C₂₁₀H₃₂₂N₄₆O₆₇
Molecular Weight：4563.1g/mol
CAS Number：2259884-03-0
3. Mazdutide Research
Mazdutide (IBI-362 / LY3305677) is a dual agonist derived from the endogenous peptide oxyntomodulin, with structural modifications designed to extend its half-life. By engaging GLP-1R (associated with satiety and glucose regulation) and GCGR (linked to energy expenditure and lipid metabolism), Mazdutide exerts complementary effects relevant to weight and metabolic outcomes.
[1] Key Phase 3 Results (GLORY-1, published in The New England Journal of Medicine):
Population: 610 adults in China with overweight or obesity.
Efficacy:
At 32 weeks: Average weight reduction of approximately −11% to −13% compared to minimal change in placebo.
At 48 weeks: Weight reduction of −12% to −15%, with a majority of participants achieving ≥5% weight loss.
Metabolic effects: Significant liver fat reduction (−63% to −73% in participants with hepatic steatosis at baseline), along with improvements in blood pressure, lipid levels, uric acid, and liver enzymes, with minimal changes in heart rate.
Reference: ClinicalTrials.gov – GLORY-1 Study
[2] Preclinical & Mechanistic Insights:
In diabetic mouse models, Mazdutide improved cognition, neuronal structure, and synaptic plasticity, showing potential neuroprotective benefits.
Dual GLP-1R/GCGR agonism enhanced satiety, thermogenesis, and lipid oxidation, supporting synergistic effects in metabolic research.
4. Future Mazdutide Research
[1] Global Phase 3 Trials:
Ongoing DREAMS-series studies are evaluating Mazdutide in type 2 diabetes and NAFLD/NASH, with promising early findings in HbA1c reduction, weight management, and liver biomarkers.
[2] Mechanistic Studies:
Research is exploring how dual GLP-1R/GCGR signaling enhances hepatocyte β-oxidation, whole-body energy expenditure, and CNS pathways related to cognition and metabolism.
[3] Comparative & Combinatorial Research:
Trials are comparing Mazdutide with semaglutide, tirzepatide, and emerging tri-agonists (e.g., retatrutide) to determine relative efficacy.
[4] Extended Formulations:
Investigations include sustained-release and depot technologies aimed at longer exposure intervals.
[5] Broader Indications:
Emerging studies are examining Mazdutide in conditions such as polycystic ovary syndrome (PCOS), alcohol-use disorder, and cardiovascular risk reduction.
5. Application Area
Research domains under active investigation include:
1. Obesity & Weight Regulation – Studies in overweight/obese populations demonstrate 10–15% average reductions in body weight, with improvements in metabolic biomarkers.
2. Type 2 Diabetes Research – Evidence of improved insulin sensitivity, HbA1c reduction, and better overall glycemic control.
3. Liver Health (NAFLD/NASH) – Up to 73% reduction in hepatic fat in participants with fatty liver disease.
4. Cardiometabolic Risk – Positive effects on lipid profiles, blood pressure, uric acid, and inflammatory markers.
5. Cognitive & Neurological Health – Preclinical models suggest neuroprotective effects that may be relevant to metabolic-cognitive disorders.
✅ Summary
Mazdutide is a novel dual GLP-1R/GCGR agonist peptide in late-stage clinical development, with strong evidence of efficacy in weight and metabolic research. Its dual mechanism addresses both energy intake and expenditure, while additional preclinical findings suggest broader potential applications in liver, cardiovascular, and neurocognitive research.
Disclaimer
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
